Page last updated: 2024-08-22

trilostane and Cancer of Liver

trilostane has been researched along with Cancer of Liver in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Chang, YC; Chen, MJ; Cheng, SP; Huang, WC; Lin, CH; Lin, JC; Liu, CL; Wu, CY	1

Other Studies

1 other study(ies) available for trilostane and Cancer of Liver

Article	Year
Trilostane, a 3β-hydroxysteroid dehydrogenase inhibitor, suppresses growth of hepatocellular carcinoma and enhances anti-cancer effects of sorafenib. Investigational new drugs, 2021, Volume: 39, Issue:6 Topics: Aged; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Dihydrotestosterone; Drug Therapy, Combination; Estradiol; Female; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Multienzyme Complexes; Progesterone Reductase; RNA, Small Interfering; Sorafenib; Steroid Isomerases; Testosterone; Xenograft Model Antitumor Assays	2021

Article

Year

Trilostane, a 3β-hydroxysteroid dehydrogenase inhibitor, suppresses growth of hepatocellular carcinoma and enhances anti-cancer effects of sorafenib.

Investigational new drugs, 2021, Volume: 39, Issue:6

Topics: Aged; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Dihydrotestosterone; Drug Therapy, Combination; Estradiol; Female; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Multienzyme Complexes; Progesterone Reductase; RNA, Small Interfering; Sorafenib; Steroid Isomerases; Testosterone; Xenograft Model Antitumor Assays

2021